MDT

85.6

-1.76%↓

118.07

-1.12%↓

VEEV

167.35

-0.11%↓

HQY

84.4

+0.63%↑

NEOG

9.24

-2.01%↓

MDT

85.6

-1.76%↓

118.07

-1.12%↓

VEEV

167.35

-0.11%↓

HQY

84.4

+0.63%↑

NEOG

9.24

-2.01%↓

MDT

85.6

-1.76%↓

118.07

-1.12%↓

VEEV

167.35

-0.11%↓

HQY

84.4

+0.63%↑

NEOG

9.24

-2.01%↓

MDT

85.6

-1.76%↓

118.07

-1.12%↓

VEEV

167.35

-0.11%↓

HQY

84.4

+0.63%↑

NEOG

9.24

-2.01%↓

MDT

85.6

-1.76%↓

118.07

-1.12%↓

VEEV

167.35

-0.11%↓

HQY

84.4

+0.63%↑

NEOG

9.24

-2.01%↓

Home・Akcijų sąrašas・Celldex Therapeutics Inc

Celldex Therapeutics Inc

Uždarymo kaina

SektoriusSveikatos priežiūra

33.75 -0.21

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

33.24

Max

33.9

Pagrindiniai rodikliai
By Trading Economics
Pajamos	-14M -81M
Pardavimai	75K 75K
Pelnas, tenkantis vienai akcijai	-1.22
Pelno marža	-108,422.667
Darbuotojai	198
EBITDA	-7.8M -81M

Rekomendacijos
By TipRanks
Rekomendacijos	Pirkti
12 mėnesių prognozė	+60.91% upside

Dividendai
By Dow Jones
Kitas uždarbis	2026-05-06

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	941M 2.6B
Ankstesnė atidarymo kaina	33.96
Ankstesnė uždarymo kaina	33.75

Naujienos nuotaikos

By Acuity

100%

337 / 348 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Weak Bullish Evidence

18.91 / 20.63 Palaikymas ir pasipriešinimas

Celldex Therapeutics Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-04-16 23:26; UTC

Karštos akcijos

Stocks to Watch: Netflix, Alcoa, Knight-Swift, NiSource

2026-04-16 20:41; UTC

Pagrindinės rinkos jėgos

Netflix Shares Slide After 2Q Outlook Misses Wall Street's Expectations

2026-04-16 23:49; UTC

Rinkos pokalbiai

Amplitude's Pivot to Oil-Linked Supply Deal Catches Bull's Eye -- Market Talk

2026-04-16 23:45; UTC

Rinkos pokalbiai

Nikkei May Decline After Hitting Record High -- Market Talk

2026-04-16 23:33; UTC

Rinkos pokalbiai

Svarbiausios naujienos

Gold Edges Higher on Hopes for U.S.-Iran Deal -- Market Talk

2026-04-16 22:51; UTC

Rinkos pokalbiai

Netflix Sees Signs That Podcasts May Boost Engagement -- Market Talk

2026-04-16 22:08; UTC

Uždarbis

Netflix Chair Reed Hastings to Leave Board in June -- 3rd Update

2026-04-16 22:06; UTC

Uždarbis

Lundin Mining: Earnings From Discontinued Ops in 1Q Expected to Be Positively Impacted by Unaudited Gain on Disposal of Eagle Mine, Totaling Approximately $4M >LUN.T

2026-04-16 22:06; UTC

Uždarbis

Lundin Mining: Pre-Announces Items Impacting 1Q Results

2026-04-16 22:06; UTC

Uždarbis

Lundin Mining: Items of Significant Impact in 1Q Expected to Include Unaudited Realized Losses on Derivative Contracts of Approximately $13M, Primarily Related to Gold Collar Contracts >LUN.T

2026-04-16 22:06; UTC

Uždarbis

Lundin Mining: Rev in 1Q Expected to Be Positively Impacted by Unaudited Provisional Pricing Adjustments on Prior-Period Concentrate Sales of Approximately $22M on Pre-Tax Basis >LUN.T

2026-04-16 22:06; UTC

Uždarbis

Lundin Mining: Adjustments Primarily Include Upward Adjustments in Relation to Prior-Period Metal Sales >LUN.T

2026-04-16 20:50; UTC

Rinkos pokalbiai

Uždarbis

Tech, Media & Telecom Roundup: Market Talk

2026-04-16 20:50; UTC

Rinkos pokalbiai

Financial Services Roundup: Market Talk

2026-04-16 20:50; UTC

Rinkos pokalbiai

Svarbiausios naujienos

Basic Materials Roundup: Market Talk

2026-04-16 20:50; UTC

Rinkos pokalbiai

Uždarbis

Health Care Roundup: Market Talk

2026-04-16 20:49; UTC

Uždarbis

SpaceX Is Ready to Go Public. The Stock Market Is Its Rocket. -- Barrons.com

2026-04-16 20:43; UTC

Uždarbis

Update: Netflix Stock Falls on Weak Guidance. Founder Reed Hastings Is Leaving the Board. -- Barrons.com

2026-04-16 20:40; UTC

Rinkos pokalbiai

Uždarbis

Global Equities Roundup: Market Talk

2026-04-16 20:40; UTC

Rinkos pokalbiai

Uždarbis

Netflix Says Engagement Quality Hits New High -- Market Talk

2026-04-16 20:30; UTC

Karštos akcijos

Stocks to Watch: TSMC, Abbott Laboratories, Nvidia, Netflix -- WSJ

2026-04-16 20:25; UTC

Uždarbis

Netflix Stock Falls on Weak Guidance. Founder Reed Hastings Is Leaving the Board. -- Barrons.com

2026-04-16 20:23; UTC

Uždarbis

These Stocks Are Today's Movers: AMD, Intel, TSMC, Abbott, Hims, Corning, Schwab, Polaris, and More -- Barrons.com

2026-04-16 20:19; UTC

Uždarbis

Netflix Guidance Disappoints. The Stock Is Down. -- Barrons.com

2026-04-16 20:17; UTC

Uždarbis

Alcoa: Alumina Costs in the Aluminum Segment Are Expected to Be Favorable by Approximately $20M Sequentially >AA

2026-04-16 20:17; UTC

Uždarbis

Alcoa: Based on Higher LME and Midwest Premium Pricing and Expected Higher Shipments, Section 232 Tariff Costs on U.S. Imports of Aluminum From Canada Expected to Increase $35M Sequentially >AA

2026-04-16 20:16; UTC

Uždarbis

Alcoa: Expects 2026 Total Aluminum Segment Production and Shipments Ranging Between 2.4M and 2.6M Metric Tons, and Between 2.6M and 2.8M Metric Tons, Respectively >AA

2026-04-16 20:16; UTC

Uždarbis

Alcoa: Expects 2026 Total Aluminum Segment Production and Shipments to Remain Unchanged From Its Prior Projection >AA

2026-04-16 20:16; UTC

Uždarbis

Alcoa: Expects 2026 Total Alumina Segment Production and Shipments Ranging Between 9.7M to 9.9M Metric Tons, and Between 11.8M and 12.0M Metric Tons, Respectively >AA

2026-04-16 20:16; UTC

Uždarbis

Alcoa: Expects 2026 Total Alumina Segment Production and Shipments to Remain Unchanged From Prior Projection >AA

Akcijų palyginimas

Kainos pokytis

Celldex Therapeutics Inc Prognozė

Kainos tikslas

By TipRanks

60.91% į viršų

12 mėnesių prognozė

Vidutinis 54.5 USD 60.91%

Aukščiausias 90 USD

Žemiausias 24 USD

Remiantis 11 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Celldex Therapeutics Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Pirkti

11 ratings

Pirkti

Laikyti

Parduoti

Remiantis 11 analitikų, pateikusių Celldex Therapeutics Inc akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Techninis įvertinimas

By Trading Central

18.91 / 20.63Palaikymas ir pasipriešinimas

Recent bullish events outweigh bearish events.

All events are bearish.

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę Celldex Therapeutics Inc

Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases. The company's clinical development programs CDX-0159, a Phase II monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity. It has research collaboration and license agreements with Yale University. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey.